Stock Track | LEADS BIOLABS-B Soars 13.24% Intraday on AACR Abstract Acceptance and Research Validation

Stock Track04-01

LEADS BIOLABS-B (09887) saw its shares soar 13.24% during intraday trading on Wednesday.

The surge follows the company's announcement that two abstracts detailing preclinical pipeline research results have been accepted for presentation at the 2026 Annual Meeting of the American Association for Cancer Research (AACR). The studies highlight the company's innovative research in T-cell engager-drug conjugates (TDCs) and dual-targeting ADCs, further validating the synergistic R&D strategy of its three core proprietary technology platforms: LeadsBody (CD3 T-Cell Engager platform), X-body (4-1BB Engager platform), and TOPiKinectics (ADC technology platform).

The company recently released its annual results, reporting full-year revenue of approximately RMB 177 million, derived from an upfront and recent milestone payment received under a licensing agreement for LBL-047. Research and development costs increased significantly as the company advanced multiple pipeline assets.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1192002926?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-04-01 12:34","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1192002926","market":"nz","top_or_hot":-1,"title":"Stock Track | LEADS BIOLABS-B Soars 13.24% Intraday on AACR Abstract Acceptance and Research Validation","media":"Stock Track","content":"<p>LEADS BIOLABS-B (09887) saw its shares soar 13.24% during intraday trading on Wednesday.</p><p>The surge follows the company's announcement that two abstracts detailing preclinical pipeline research results have been accepted for presentation at the 2026 Annual Meeting of the American Association for Cancer Research (AACR). The studies highlight the company's innovative research in T-cell engager-drug conjugates (TDCs) and dual-targeting ADCs, further validating the synergistic R&D strategy of its three core proprietary technology platforms: LeadsBody (CD3 T-Cell Engager platform), X-body (4-1BB Engager platform), and TOPiKinectics (ADC technology platform).</p><p>The company recently released its annual results, reporting full-year revenue of approximately RMB 177 million, derived from an upfront and recent milestone payment received under a licensing agreement for LBL-047. Research and development costs increased significantly as the company advanced multiple pipeline assets.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | LEADS BIOLABS-B Soars 13.24% Intraday on AACR Abstract Acceptance and Research Validation</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | LEADS BIOLABS-B Soars 13.24% Intraday on AACR Abstract Acceptance and Research Validation\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2026-04-01 12:34</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>LEADS BIOLABS-B (09887) saw its shares soar 13.24% during intraday trading on Wednesday.</p><p>The surge follows the company's announcement that two abstracts detailing preclinical pipeline research results have been accepted for presentation at the 2026 Annual Meeting of the American Association for Cancer Research (AACR). The studies highlight the company's innovative research in T-cell engager-drug conjugates (TDCs) and dual-targeting ADCs, further validating the synergistic R&D strategy of its three core proprietary technology platforms: LeadsBody (CD3 T-Cell Engager platform), X-body (4-1BB Engager platform), and TOPiKinectics (ADC technology platform).</p><p>The company recently released its annual results, reporting full-year revenue of approximately RMB 177 million, derived from an upfront and recent milestone payment received under a licensing agreement for LBL-047. Research and development costs increased significantly as the company advanced multiple pipeline assets.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"09887","symbol_name":"维立志博-B","start_time":0,"source_url":"","article_id":"1192002926","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1192002926","pubTimestamp":1775018058,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"LEADS BIOLABS-B (09887) saw its shares soar 13.24% during intraday trading on Wednesday.The surge follows the company's announcement that two abstracts detailing preclinical pipeline research results...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"09887":"维立志博-B"},"translate_title":"个股追踪|领涨BIOLABS-B盘中大涨13.24%因AACR摘要接受及研究验证","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"09887":1},"content_text":"LEADS BIOLABS-B (09887) saw its shares soar 13.24% during intraday trading on Wednesday.The surge follows the company's announcement that two abstracts detailing preclinical pipeline research results have been accepted for presentation at the 2026 Annual Meeting of the American Association for Cancer Research (AACR). The studies highlight the company's innovative research in T-cell engager-drug conjugates (TDCs) and dual-targeting ADCs, further validating the synergistic R&D strategy of its three core proprietary technology platforms: LeadsBody (CD3 T-Cell Engager platform), X-body (4-1BB Engager platform), and TOPiKinectics (ADC technology platform).The company recently released its annual results, reporting full-year revenue of approximately RMB 177 million, derived from an upfront and recent milestone payment received under a licensing agreement for LBL-047. Research and development costs increased significantly as the company advanced multiple pipeline assets.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"2","news_tag":"movement","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.40.0","shortVersion":"4.40.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1192002926","isCrawlerRequest":true}